Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis

BACKGROUND: Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs...

Descripció completa

Dades bibliogràfiques
Autors principals: Akter, Ripa, Maksymowych, Walter P., Martin, M. Liam, Hogan, David B.
Format: Online Article Text
Idioma:English
Publicat: Canadian Geriatrics Society 2020
Matèries:
Original Research
Accés en línia:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Ítems similars